

## Research Article

# Characterization of Polysaccharides Extracted from *Sargassum fusiforme* and Its Effective Prevention of Contrast-Induced Nephropathy via Enhancing Antioxidant Capacity

Min Dai,<sup>1,2,3</sup> Ying-Ling Zhou <sup>1,2</sup> Tao Jiang,<sup>3</sup> Cai-Dong Luo,<sup>3</sup> Hu Wang,<sup>3</sup> Wei Du,<sup>3</sup> and Min Wang<sup>3</sup>

<sup>1</sup>The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China

<sup>2</sup>Department of Cardiovascular Medicine, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China

<sup>3</sup>Department of Cardiovascular Medicine, Mianyang Central Hospital, Mianyang, Sichuan 621000, China

Correspondence should be addressed to Ying-Ling Zhou; [zylgdh@163.com](mailto:zylgdh@163.com)

Received 20 June 2019; Revised 30 October 2019; Accepted 8 November 2019; Published 26 December 2019

Guest Editor: Di Li

Copyright © 2019 Min Dai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Contrast-induced nephropathy (CIN) is a common complication in patients with coronary arteriography, and oxidative stress is involved in the CIN pathogenesis. *Sargassum fusiforme* (SF) is a brown seaweed with medicinal value, and its polysaccharides have good antioxidant activity. In this study, the crude polysaccharides (cSFP-C) were extracted by cold water, precipitated by ethanol, purified by  $\text{CaCl}_2$ , and detected with high contents of sulfate radical and fucose. cSFP-C is composed of glucose, glucuronic acid, xylose, rhamnose, mannose, galactose, and fucose with a molar ratio of 1.0:0.4:5.6:1.2:1.7:12.3:56.1. The cSFP-C has the typical absorption of polysaccharides. Antioxidation assays *in vitro* showed that cSFP-C exhibited superoxide radical scavenging activity which was better than the hot water-extracted crude polysaccharides (cSFP-H). 20 rats were divided into 4 groups ( $n = 5$ ): sham group; CIN group; CIN+cSFP-C group, and cSFP-C group. The CIN+cSFP-C group and cSFP-C group were pretreated intragastrically with cSFP-C at a dose of 9.45 g/kg twice daily for 5 consecutive days. Then, the CIN group and CIN+cSFP-C group were given indomethacin to develop CIN. The *in vivo* results showed that cSFP-C could decrease blood creatinine and urea nitrogen, inhibiting pathological injury in the renal tissues. The MDA content of renal tissues was decreased, while the activity of SOD was increased. The crude sulfated polysaccharides extracted from *S. fusiforme* have a renoprotective effect on oxidative stress to alleviate the kidney injury in CIN rats.

## 1. Introduction

With the raised morbidity of coronary atherosclerosis heart diseases, and the marked progress in intravascular interventional radiology, the volume of patients with percutaneous coronary intervention (PCI) has been growing significantly, with the number of PCI centers [1] increasing to 21.2% during 2003~2011. However, among the complications of PCI, the incidence of contrast-induced nephropathy (CIN) ranges from 3% to approximately 30% [2, 3], which has become the third leading cause of hospital-acquired acute kidney injury (AKI) following nephrotoxic drugs and renal perfusion insufficiency [4, 5]. After CIN occurs, the hospital

days, the dialysis population, and the late cardiovascular events increase.

So far, there is still lack of therapeutic measures to reverse CIN. Effective prevention and treatment are needed. The commonly used agents are iodine contrasts in PCI, which are mostly unchanged passing through the kidneys into the urine, so as to have a damaging effect on the kidneys. The mechanisms of CIN have not been completely elucidated currently. Previous studies reported that CIN is a complex pathological process related to multiple pathological cascades. Oxidative stress [6, 7], renal ischemia [8], endothelial dysfunction [9], inflammation [10, 11], apoptosis [12–14], and tubular transport dysfunction [15] may be involved

in the pathogenesis of CIN. Increasing studies point out that reactive oxygen species (ROS) play the key role in CIN development [16–18]. In accordance with this, several potent ROS scavenging compounds are proved effective for preventing CIN.

Natural antioxidants extracted from plants may retard renal damage and may be an effective, safe, and economical therapy for organ protection. *Sargassum fusiforme* (SF) is an edible brown seaweed. SF can be used for kidney disease treatment in traditional Chinese medicine (TCM) and is documented in the medical books, such as *Shennong's Classic of Materia Medica*, *Compendium of Materia Medica*, and TCM prescriptions of *Coneha Ostreae Rhizoma Alismatis Powder* invented by Zhang Zhongjing. It was reported to be inhibitive to renal interstitial fibrosis caused by unilateral ureteral obstruction. Sulfated polysaccharides are the most important component of SF, mainly accumulated in the cell wall matrix. The complicated molecular structures of polysaccharides partly contribute to its multiple biological functions [19]. Sulfur-containing groups, such as sulfonate and sulfate, can be part of some natural polysaccharides and provide the polysaccharides more diversity [20, 21]. The sulfated polysaccharides are also called fucoidan from SF, which shows antioxidation, anti-inflammation, antitumor, antiradiation, and anticoagulation effects. It has also been reported that fucoidan extracted from SF increases the activity of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) *in vivo* [22] and reduces lipid peroxidation products. So far, there is no report for the renal-protective effect of fucoidan from SF in a CIN animal model. This study reports on the preparation of fucoidan from SF, evaluation in antioxidant defense *in vitro*, and the antioxidative effects against CIN *in vivo*.

## 2. Materials and Methods

**2.1. Materials.** *Sargassum fusiforme* was collected from Rongcheng in Shandong, China. Reagents and solvents in the study were of analytical purity (AR) grade and purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).

**2.2. Sample Pretreatment.** The parameters of the crude polysaccharide extraction are given in Figure 1. SF was dried at 50°C, ground by a high-speed disintegrator into a powder, and sieved through a 4-mesh screen. 95% methanol was used to remove the fat of the sieved powder (1 : 10 g/ml) by refluxing at 40°C for 24 h. Afterwards, the defatted residue was dried at 40°C for subsequent experiments.

**2.3. Extraction of Crude Polysaccharides from SF.** The defatted powder was extracted three times with water (1 : 30 g/ml) at room temperature for 3 h. The leaching solutions were filtered and concentrated with a rotary evaporator (Yarong, Shanghai, China) at 40°C under vacuum. 95% ethanol was used to precipitate polysaccharides at room temperature overnight. The residue was collected by filter and reprecipitated in 95% ethanol. After being filtered and lyophilized, the powder was redissolved in calcium chloride solution (4 M) with stirring until no precipitation appeared. Then, repeat the precipitation




FIGURE 1: The flowchart of the extraction of the crude polysaccharides from *Sargassum fusiforme*.

by using 80% ethanol and 95% ethanol. Finally, the lyophilized powder was redissolved and exhaustively dialyzed (10 kDa molecular weight cutoff) against distilled water for 72 h to remove soluble impurities. By lyophilization, the crude polysaccharides were named as cSFP-C. The hot water-extracted crude polysaccharides, cSFP-H, were extracted three times with water (1 : 30 g/ml) for 3 h at 80°C, but not room temperature. The other steps were the same. The cSFP-C and cSFP-H were weighted and calculated the extraction yield (Y) according to the following equation:

$$Y (\%) = \frac{\text{weight of the crude polysaccharides}}{\text{weight of dry } Sargassum fusiforme} \times 100. \quad (1)$$

**2.4. Determination of Chemical Composition of cSFP-C.** The total sugar content in cSFP-C was determined using the phenol-sulfuric acid method. The sulfate radical content was estimated by the barium chloride-gelatin method [23]. The total uronic acid content was tested by the m-phenylphenol method using glucuronic acid as the standard [24]. The protein content was analyzed by Coomassie brilliant blue method with bovine serum albumin as the standard [25].

**2.5. Measurement of Monosaccharide Components.** 2 mg cSFP-C was mixed with 1 ml trifluoroacetic acid (TFA, 2 M) and then heated at 120°C for 2 h. After being dried with rotary evaporation, 1 ml of methyl alcohol was added to the hydrolyzed product to completely remove TFA, three times. The product and monosaccharide standards were prederivatized with 1-phenyl-3-methyl-5-pyrazolone (PMP). The HPLC system (Waters 1525, Milford, USA) and UV detector (Waters 2487) were used to analyze the monosaccharide components with a wavelength of 254 nm. The monosaccharide

quantification in cSFP-C was analyzed by comparing with the monosaccharide standard curves.

**2.6. Fourier-Transform Infrared Spectroscopic Analysis (FT-IR).** The dried cSFP-C was prepared as KBr pellets for the IR spectra measurement in a range of 4000 to 400  $\text{cm}^{-1}$  using a Nicolet Nexus FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).

**2.7. Superoxide Radical Scavenging Activity Measured by PMS-NADH-NBT.** Superoxide anion scavenging activity was detected by the PMS-NADH-NBT method reported by Nishikimi et al. [26] with slight modification. The reaction system contained 0.15 ml NADH (166  $\mu\text{mol/l}$ ), 0.45 ml NBT (86  $\mu\text{mol/l}$ ), and varying concentrations of cSFP-C (0 mg/ml~2 mg/ml). Then, 0.15 ml PMS (16.2  $\mu\text{mol/l}$ ) was used to generate a superoxide radical and start the reaction. The mixture was incubated at room temperature for 5 min, and the absorbance was measured at a wavelength of 560 nm. In the blank control, there was 0 mg/ml cSFP-C in the buffer. The following equation was used to calculate the effect on scavenging superoxide radical:

$$\text{Scavenging effect (\%)} = \frac{A(\text{blank}) - A(\text{cSFP})}{A(\text{blank})} \times 100. \quad (2)$$

**2.8. Rat Model of CIN and Treatment.** 20 Wistar rats were divided into 4 groups of 5 rats each as follows: (1) sham rats given saline, (2) CIN rats with induced CIN, (3) CIN+cSFP-C rats pretreated with cSFP-C followed by the CIN induction, and 4) cSFP-C rats pretreated with cSFP-C. CIN+cSFP-C and cSFP-C rats were orally administrated 5.67 g/kg cSFP-C twice daily at 7 a.m. and 15 p.m. for 5 days. The dose of cSFP-C in this study was threefold the dose recommended by the Chinese Pharmacopoeia in clinic [27]. Sham and CIN rats were given saline. After pretreatment with cSFP-C or saline, CIN was developed in CIN and CIN+cSFP-C rats on the basis of previously described reports [28]. Briefly, under pentobarbital sodium anesthesia, rats were given 10 mg/kg indomethacin, followed 10 mg/kg NW-nitro-L-arginine methyl ester (L-NAME) 15 min later and 1600 mg iodine/kg of iopromide 30 min later. Sham and cSFP-C rats were given saline at each time point. All rats were sacrificed 24 h after CIN induction. Serum was isolated from the blood for renal biochemical and inflammatory testing. The kidneys were removed for histopathological investigation and oxidative stress detection.

**2.9. Biochemical Parameters.** Blood urea nitrogen (BUN) and creatinine were measured using an AU5800 autoanalyzer (Beckman Coulter, USA).

**2.10. Histopathological Investigation.** One side of the kidney was fixed in 10% formalin for 24 h and subsequently embedded in paraffin. Then 4  $\mu\text{m}$  thickness sections were stained with hematoxylin and eosin.

**2.11. Detection of Oxidative Stress Markers.** One side of the kidney was homogenated using ice-cold saline and then centrifuged. The supernatant was collected and the levels of SOD

TABLE 1: Yield and chemical components of cSFP-C.

Yield (%)	Total sugar (%)	Sulfate radical (%)	Uronic acid (%)	Proteins (%)
7.5	85.5	19.3	8.3	0.3

and MDA were measured using commercial kits (Nanjing Jiancheng, Jiangsu, China).

### 3. Results and Discussion

**3.1. Yield and Chemical Compositions of cSFP.** The yields of cSFP-C and cSFP-H from dry SF were 7.5% and 9.1%, respectively. The chemical compositions of cSFP-C (total sugar, sulfate radical, uronic acid, and proteins) are summarized in Table 1. The total sugar was the major constituent of cSFP-C, achieving 85.5%, with small amounts of protein at 0.3%. The contents of sulfate radical and uronic acid were 19.3% and 8.3%, respectively. The fucoidan extraction using cold water combined with calcium-alginate precipitation has not been investigated. Since calcium chloride could precipitate calcium-alginate, the fucoidan purity in cSFP-C can be enhanced [29]. Compared with the previous study by Chen et al. [22], the uronic acid percentage was significantly decreased and the sulfate radical percentage was significantly increased with the procedure for calcium-alginate precipitation.

**3.2. Quantitative Analysis of Monosaccharide Components.** To further investigate the monosaccharide composition of extracted cSFP-C, HPLC was run and its retention time was used to quantify the monosaccharide amount normalized to glucose (Figure 2). The quantitative results are summarized specifically in Table 2. Predominantly fucose was found, and abundant galactose was a high component among different monosaccharides. This result was consistent with previous reported findings for components of fucose and galactose, which showed that fucose made up the largest proportion followed by galactose [30–32]. However, glucuronic acid content significantly decreased with 0.4 molar ratio to glucose, which indicated an optimized purity of fucoidan. Glucuronic acid content is much lower than those previous reported findings, perhaps due to the procedure for calcium-alginate precipitation [32, 33]. In addition, it was found that cSFP is composed of glucose, xylose, rhamnose, and mannose.

**3.3. FT-IR Analysis.** The FT-IR spectrum provides important information about the conformation and functional groups of cSFP-C in Figure 3. cSFP-C exhibited a strong and broad area of absorption between 3600 and 3200  $\text{cm}^{-1}$ , representing O-H stretching vibration. A band was observed at 1635  $\text{cm}^{-1}$  for the carboxylate stretching [34]. The absorption peak at 3000~2800  $\text{cm}^{-1}$  indicated the presence of the C-H stretching vibration. The signal at 1251  $\text{cm}^{-1}$  could be associated with the asymmetric O=S=O stretching vibration of sulfate esters [30]. The absorption peak at 821  $\text{cm}^{-1}$  was assigned to the sulfate groups [35].




FIGURE 2: HPLC separation of PMP-labeled monosaccharide composition of cSFP-C: (a) monosaccharides standard; (b) cSFP-C. Peaks: 1: mannose; 2: rhamnose; 3: glucuronic acid; 4: glucose; 5: galactose; 6: xylose; 7: fucose.

TABLE 2: Molar ratio of monosaccharide composition in cSFP-C.

Glc	GlcA	Xyl	Rha	Man	Gal	Fuc
1.0	0.4	5.6	1.2	1.7	12.3	56.1

Notes: Glc: glucose; GlcA: glucuronic acid; Xyl: xylose; Rha: rhamnose; Man: mannose; Gal: galactose; Fuc: fucose.




FIGURE 3: FT-IR spectrum of cSFP-C.

**3.4. Scavenging Activity of Superoxide Radical by cSFP-C.** cSFP-C showed a significant scavenging ability on the superoxide radical in a concentration-dependent manner in Figure 4. Decreased absorbance and increased scavenging effect (%) were present as the cSFP-C concentration increased. All kinds of free radicals are generated in oxidative metabolism, in which the superoxide anion free radical is produced at the earliest [36]. Then, superoxide radical produces other free radicals through disproportionation reaction [37] and also causes lipid peroxidation [38]. Thus, the scavenging for superoxide radical is crucial for the protection of the cells from oxidative damage. As studied previously, hot water extraction, as the traditional procedure, has been widely investigated for the polysaccharide extraction from SF [39, 40]. However, Chen et al. [22] reported that hot water-extracted polysaccharides performed less free radical (superoxide radical) scavenging activity *in vitro* compared to cold water-extracted polysaccharides. In this study, it could




FIGURE 4: Scavenging effect on superoxide radicals by cSFP-C and cSFP-H. Values are means  $\pm$  S.D. ( $n = 3$ ).

be seen that the extracted cSFP-C showed good scavenging ability on the superoxide radical compared to cSFP-H (Figure 4). The result was consistent with the result reported by Chen et al. [22]. It indicated that cSFP-C might have some pharmacological effects according to its antioxidative activity.

**3.5. cSFP-C Prevents Iopromide-Induced Renal Dysfunction in CIN Rats.** As shown in Figure 5, levels of blood urea nitrogen (BUN) and creatinine of CIN rats were significantly higher than those of sham rats ( $P < 0.05$ ), indicating that iopromide caused renal dysfunction. Compared with CIN rats, CIN+cSFP-C rats significantly reduced BUN and creatinine levels ( $P < 0.05$ ), suggesting that cSFP-C preadministration played a role in renoprotection. Compared with sham rats, cSFP-C rats did not affect BUN and creatinine levels, suggesting that a high dose of cSFP-C had no renal injury. Sulfated polysaccharides, as the major bioactive components of seaweed, have demonstrated various biological effects. Li et al. [41] reported that sulfated polysaccharides from seaweed *Laminaria japonica* markedly decrease BUN and creatinine levels. Chen et al. [42] found that fucoidan from *Sargassum hemiphyllum* inhibits serum creatinine and improves renal function in mice with chronic kidney disease (CKD). Due to the high contents of sulfate radical and fucose, it was speculated that the reduced BUN and creatinine levels in






FIGURE 5: cSFP pretreatment mitigated renal injury against CIN: (a) serum creatinine concentration; (b) serum urea nitrogen concentration. \* $P < 0.05$  versus sham rats; # $P < 0.05$  versus CIN rats.

CIN+cSFP-C rats were partially due to the high content of fucoidan in cSFP-C.

**3.6. Protective Effect of cSFP on the Kidney.** As shown in Figure 6, in the sham group, no significant histological changes were observed, while CIN rats showed severe damage, including lesions of tubular necrosis and inflammatory cell infiltration. In the CIN+cSFP-C group, cSFP-C pretreatment significantly reduced these types of damage, indicating that cSFP-C could protect the kidney of CIN rats from damage. This result was in accordance with the renal biochemical results. It was reported that sulfated polysaccharides reduce renal tubulointerstitial fibrosis in CKD mice [42]. And low molecular weight fucoidan inhibits epithelial mesenchymal transition of human renal proximal tubular cells [43]. These results enlightened us to seek out the underlying mechanism for renoprotection of cSFP-C.

**3.7. cSFP Protected the Kidney from Oxidative Stress.** In order to evaluate whether cSFP-C protects renal tissue of CIN rats from oxidative stress, SOD activity and MDA content in renal tissue were detected. MDA content of CIN rats was significantly higher than that of sham rats, while SOD activity was significantly reduced ( $P < 0.05$ ). Although the pathological mechanism of CIN has not been clearly elucidated, various studies have investigated that oxidative stress is an important cause of CIN [6, 44]. The direct toxicity of contrast agents leads to the ROS production, while the oxidative stress caused by the increasing free radicals leads to the apoptosis of renal tubules and glomerular cells [45]. These results in Figure 7 showed the deterioration on oxidative stress, suggesting the coincidence with the pathological deterioration. According to the mechanism of ROS-promoted development of CIN, the corresponding removal of ROS has been studied in preclinical and clinical studies. Sodium bicarbonate [46], n-acetylcysteine (NAC) [47], theophylline [48, 49], dopamine [50], furosemide [51], mannitol [52], and ascorbic acid [53] have been studied in the clinical prevention of CIN. In preclinical studies, the protective effects of melatonin [54], tocopherol [55, 56], and L-carnitine [57] have also been studied with regard to CIN. In this study, when cSFP-C was preadministered, the MDA content was significantly decreased and SOD activity was




FIGURE 6: cSFP pretreatment attenuated the renal pathological damage in kidney tissues of CIN rats. Renal histological sections by H&E staining at 24 h CIN induction (100x).

significantly restored ( $P < 0.05$ ). These results showed that preadministration of cSFP-C largely reduces the oxidative stress damage in kidneys of CIN rats and improves the endogenous antioxidative capacity of the kidneys. These results *in vivo* were also in accordance with the scavenging activity of the superoxide radical by cSFP-C *in vitro*. In addition, cSFP-C did not affect SOD activity and MDA content compared with the sham group.

## 4. Conclusion

In summary, the polysaccharides were purified from *Sargassum fusiforme* (SF) and contained abundant sulfate radical and predominant fucose, which indicated potential bioactivity. Then, the polysaccharides exhibited the scavenging activity for superoxide radical *in vitro*. According to the antioxidative effect, the polysaccharides demonstrated renoprotective properties against CIN *in vivo*. The pretreatment of cSFP-C could effectively improve biochemical indexes and pathological structures and correct the renal dysfunction




FIGURE 7: cSFP pretreatment reduced the renal oxidative stress in kidney tissues of CIN rats: (a) renal MDA concentration; (b) renal SOD activity. \* $P < 0.05$  versus sham rats; # $P < 0.05$  versus CIN rats.

and the abnormal levels of MDA and SOD. It can be speculated that the renoprotective effects of cSFP-C might be mediated by inhibition of oxidative stress.

### Data Availability

All the data is available in the handwritten notebook documented in our lab.

### Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

### Acknowledgments

This work was supported by the Medical Scientific Research Foundation of Guangdong Province of China (No. A2017194).

### References

- [1] J. R. Langabeer, T. D. Henry, D. J. Kereiakes et al., "Growth in percutaneous coronary intervention capacity relative to population and disease prevalence," *Journal of the American Heart Association*, vol. 2, no. 6, article e000370, 2013.
- [2] Y. Yuan, H. Qiu, X. Y. Hu et al., "Relationship between high level of estimated glomerular filtration rate and contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention," *Chinese Medical Journal*, vol. 131, no. 17, pp. 2041–2048, 2018.
- [3] Y. Liu, Y. H. Liu, J. Y. Chen et al., "Safe contrast volumes for preventing contrast-induced nephropathy in elderly patients with relatively normal renal function during percutaneous coronary intervention," *Medicine*, vol. 94, no. 12, article e615, 2015.
- [4] R. Inokuchi, Y. Hara, H. Yasuda, N. Itami, Y. Terada, and K. Doi, "Differences in characteristics and outcomes between community- and hospital-acquired acute kidney injury: a systematic review and meta-analysis," *Clinical Nephrology*, vol. 88, no. 10, pp. 167–182, 2017.
- [5] S. Ali-Hasan-Al-Saegh, S. J. Mirhosseini, Z. Ghodrati-pour et al., "Protective effects of anti-oxidant supplementations on contrast-induced nephropathy after coronary angiography: an updated and comprehensive meta-analysis and systematic review," *Kardiologia Polska*, vol. 74, no. 7, pp. 610–626, 2016.
- [6] O. Ozturk, H. A. Eroglu, S. Ustebay, M. Kuzucu, and Y. Adali, "An experimental study on the preventive effects of N-acetyl cysteine and ozone treatment against contrast-induced nephropathy," *Acta Cirúrgica Brasileira*, vol. 33, no. 6, pp. 508–517, 2018.
- [7] A. Pisani, E. Riccio, M. Andreucci et al., "Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy," *BioMed Research International*, vol. 2013, Article ID 868321, 6 pages, 2013.
- [8] A. Diamantopoulos, I. Kyriazis, K. Geronatsiou et al., "Parstatin prevents renal injury following ischemia/reperfusion and radiocontrast administration," *American Journal of Nephrology*, vol. 36, no. 3, pp. 278–286, 2012.
- [9] M. R. Ardalan, A. Rastegar, R. S. Tubbs, and M. M. Shoja, "Contrast-induced nephropathy as an indicator of diffuse endothelial dysfunction: introducing novel therapeutic options for decreasing the long-term mortality," *Medical Hypotheses*, vol. 69, no. 4, pp. 961–962, 2007.
- [10] R. Solomon and H. L. Dauerman, "Contrast-induced acute kidney injury," *Circulation*, vol. 122, no. 23, pp. 2451–2455, 2010.
- [11] X. F. Guan, Q. J. Chen, X. C. Zuo et al., "Contrast media-induced renal inflammation is mediated through HMGB1 and its receptors in human tubular cells," *DNA and Cell Biology*, vol. 36, no. 1, pp. 67–76, 2017.
- [12] X. He, J. Yang, L. Li et al., "Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro," *Molecular Medicine Reports*, vol. 15, no. 4, pp. 1963–1972, 2017.
- [13] J. H. Rundback, D. Nahl, and V. Yoo, "Contrast-induced nephropathy," *Journal of Vascular Surgery*, vol. 54, no. 2, pp. 575–579, 2011.
- [14] M. M. Sendeski, "Pathophysiology of renal tissue damage by iodinated contrast media," *Clinical and Experimental Pharmacology & Physiology*, vol. 38, no. 5, pp. 292–299, 2011.
- [15] S. N. Heyman, C. Rosenberger, S. Rosen, and M. Khamaisi, "Why is diabetes mellitus a risk factor for contrast-induced nephropathy?," *BioMed Research International*, vol. 2013, Article ID 123589, 8 pages, 2013.
- [16] Z. Zhao, G. Liao, Q. Zhou, D. Lv, H. Holthfer, and H. Zou, "Sulforaphane attenuates contrast-induced nephropathy in rats via Nrf2/HO-1 pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 9825623, 12 pages, 2016.
- [17] R. Liang, Q. Zhao, G. Jian et al., "Tanshinone IIA attenuates contrast-induced nephropathy via Nrf2 activation in rats,"

- Cellular Physiology and Biochemistry*, vol. 46, no. 6, pp. 2616–2623, 2018.
- [18] A. Börekçi, M. Gür, C. Türkoğlu et al., “Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention,” *Angiology*, vol. 66, no. 4, pp. 339–345, 2015.
  - [19] J. Y. Li, Y. J. Yu, K. Myungwoong et al., “Manipulation of cell adhesion and dynamics using RGD functionalized polymers,” *Journal of Materials Chemistry B*, vol. 5, no. 31, pp. 6307–6316, 2017.
  - [20] Y. Li, T. Yang, Y. Yu et al., “Combinatorial library of chalcogen-containing lipidoids for intracellular delivery of genome-editing proteins,” *Biomaterials*, vol. 178, pp. 652–662, 2018.
  - [21] L. Zhang, Y. Yu, C. Joubert et al., “Differentiation of dental pulp stem cells on Gutta-Percha scaffolds,” *Polymers*, vol. 8, no. 5, p. 193, 2016.
  - [22] P. Chen, D. He, Y. Zhang et al., “*Sargassum fusiforme* polysaccharides activate antioxidant defense by promoting Nrf2-dependent cytoprotection and ameliorate stress insult during aging,” *Food & Function*, vol. 7, no. 11, pp. 4576–4588, 2016.
  - [23] Y. Sun, H. Liang, G. Cai et al., “Sulfated modification of the water-soluble polysaccharides from *Polyporus albicans* mycelia and its potential biological activities,” *International Journal of Biological Macromolecules*, vol. 44, no. 1, pp. 14–17, 2009.
  - [24] T. M. C. C. Filisetti-Cozzi and N. C. Carpita, “Measurement of uronic acids without interference from neutral sugars,” *Analytical Biochemistry*, vol. 197, no. 1, pp. 157–162, 1991.
  - [25] M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” *Analytical Biochemistry*, vol. 72, no. 1–2, pp. 248–254, 1976.
  - [26] M. Nishikimi, N. Appaji Rao, and K. Yagi, “The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen,” *Biochemical and Biophysical Research Communications*, vol. 46, no. 2, pp. 849–854, 1972.
  - [27] Chinese Pharmacopoeia Commission, *Chinese Pharmacopoeia*, People’s Medical Publishing House, 4th ed edition, 2015.
  - [28] N. Wang, R. B. Wei, Q. P. Li et al., “Renal protective effect of probucol in rats with contrast-induced nephropathy and its underlying mechanism,” *Medical Science Monitor*, vol. 21, pp. 2886–2892, 2015.
  - [29] A. Haug and O. Smidsrød, “Fractionation of alginates by precipitation with calcium and magnesium ions,” *Acta Chemica Scandinavica*, vol. 19, pp. 1221–1226, 1965.
  - [30] L. Chen, P. Chen, J. Liu et al., “*Sargassum fusiforme* polysaccharide SFP-F2 activates the NF- $\kappa$ B signaling pathway via CD14/IKK and P38 axes in RAW264.7 cells,” *Marine Drugs*, vol. 16, no. 8, p. 264, 2018.
  - [31] P. Hu, Z. Li, M. Chen et al., “Structural elucidation and protective role of a polysaccharide from *Sargassum fusiforme* on ameliorating learning and memory deficiencies in mice,” *Carbohydrate Polymers*, vol. 139, pp. 150–158, 2016.
  - [32] B. Li, X. J. Wei, J. L. Sun, and S. Y. Xu, “Structural investigation of a fucoidan containing a fucose-free core from the brown seaweed, *Hizikia fusiforme*,” *Carbohydrate Research*, vol. 341, no. 9, pp. 1135–1146, 2006.
  - [33] Y. Ye, D. Ji, L. You, L. Zhou, Z. Zhao, and C. Brennan, “Structural properties and protective effect of *Sargassum fusiforme* polysaccharides against ultraviolet B radiation in hairless Kun Ming mice,” *Journal of Functional Foods*, vol. 43, pp. 8–16, 2018.
  - [34] T. M. A. Silva, L. G. Alves, K. C. S. de Queiroz et al., “Partial characterization and anticoagulant activity of a heterofucan from the brown seaweed *Padina gymnospora*,” *Brazilian Journal of Medical and Biological Research*, vol. 38, no. 4, pp. 523–533, 2005.
  - [35] S. A. Foley, E. Szegezdi, B. Mulloy, A. Samali, and M. G. Tuohy, “An unfractionated fucoidan from *Ascophyllum nodosum*: extraction, characterization, and apoptotic effects in vitro,” *Journal of Natural Products*, vol. 74, no. 9, pp. 1851–1861, 2011.
  - [36] V. Lobo, A. Patil, A. Phatak, and N. Chandra, “Free radicals, antioxidants and functional foods: impact on human health,” *Carbohydrate Research*, vol. 4, no. 8, p. 118, 2010.
  - [37] B. H. J. Bielski and A. O. Allen, “Mechanism of the disproportionation of superoxide radicals,” *The Journal of Physical Chemistry*, vol. 81, no. 11, pp. 1048–1050, 1977.
  - [38] M. Repetto, J. Semprine, and A. Boveris, “Lipid peroxidation: chemical mechanism, biological implications and analytical determination,” in *Lipid Peroxidation*, Angel Catala, Intech Open, 2012.
  - [39] Y. H. Sun, X. L. Chen, S. Liu et al., “Preparation of low molecular weight *Sargassum fusiforme* polysaccharide and its anticoagulant activity,” *Journal of Oceanology and Limnology*, vol. 36, no. 3, pp. 882–891, 2018.
  - [40] Y. J. Li, X. T. Fu, D. L. Duan, J. C. Xu, and X. Gao, “Comparison study of bioactive substances and nutritional components of brown algae *Sargassum fusiforme* strains with different vesicle shapes,” *Journal of Applied Phycology*, vol. 30, no. 6, pp. 3271–3283, 2018.
  - [41] X. Li, J. Wang, H. Zhang, and Q. Zhang, “Renoprotective effect of low-molecular-weight sulfated polysaccharide from the seaweed *Laminaria japonica* on glycerol-induced acute kidney injury in rats,” *International Journal of Biological Macromolecules*, vol. 95, pp. 132–137, 2017.
  - [42] C. H. Chen, Y. M. Sue, C. Y. Cheng et al., “Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway,” *Scientific Reports*, vol. 7, no. 1, article 40183, 2017.
  - [43] X. Li, X. Li, Q. Zhang, and T. Zhao, “Low molecular weight fucoidan and its fractions inhibit renal epithelial mesenchymal transition induced by TGF- $\beta$ 1 or FGF-2,” *International Journal of Biological Macromolecules*, vol. 105, Part 2, pp. 1482–1490, 2017.
  - [44] C. Mamoulakis, K. Tsarouhas, I. Fragkiadoulaki et al., “Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies,” *Pharmacology & Therapeutics*, vol. 180, pp. 99–112, 2017.
  - [45] S. Detrenis, M. Meschi, S. Musini, and G. Savazzi, “Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art,” *Nephrology, Dialysis, Transplantation*, vol. 20, no. 8, pp. 1542–1550, 2005.
  - [46] M. Pakfetrat, L. Malekmakan, Z. Salmanpour, M. H. Nikoo, and P. Izadpanah, “Comparison of normal saline, Ringer’s lactate, and sodium bicarbonate for prevention of contrast-induced nephropathy in patients with coronary angiography: a randomized double-blind clinical trial,” *Indian Journal of Nephrology*, vol. 29, no. 1, pp. 22–27, 2019.

- [47] Y. Feng, X. Huang, L. Li, and Z. Chen, "N-Acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: a meta-analysis," *Nephrology*, vol. 23, no. 6, pp. 530–538, 2018.
- [48] M. Arabmomeni, J. Najafian, M. Abdar Esfahani, M. Samadi, and L. Mirbagher, "Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy," *ARYA Atherosclerosis*, vol. 11, no. 1, pp. 43–49, 2015.
- [49] M. E. M. Bilasy, M. A. Oraby, H. M. Ismail, and F. A. Maklady, "Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures," *Journal of Interventional Cardiology*, vol. 25, no. 4, pp. 404–410, 2012.
- [50] J. Choi, H. Lee, D. Chang et al., "Effect of dopamine on excretory urographic image quality and the prevention of contrast-induced nephropathy in dogs," *The Journal of Veterinary Medical Science*, vol. 63, no. 4, pp. 383–388, 2001.
- [51] N. Duan, J. Zhao, Z. Li et al., "Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis of randomized controlled trials," *Medical Science Monitor*, vol. 21, pp. 292–297, 2015.
- [52] S. R. Majumdar, C. M. Kjellstrand, W. J. Tymchak, M. Hervas-Malo, D. A. Taylor, and K. K. Teo, "Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial," *American Journal of Kidney Diseases*, vol. 54, no. 4, pp. 602–609, 2009.
- [53] E. Palli, D. Makris, J. Papanikolaou et al., "The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study," *Critical Care*, vol. 21, no. 1, p. 269, 2017.
- [54] D. Onk, O. A. Onk, K. Turkmen et al., "Melatonin attenuates contrast-induced nephropathy in diabetic rats: the role of interleukin-33 and oxidative stress," *Mediators of Inflammation*, vol. 2016, Article ID 9050828, 10 pages, 2016.
- [55] M. Monami, A. Cignarelli, S. Pinto et al., "Alpha-tocopherol and contrast-induced nephropathy: a meta-analysis of randomized controlled trials," *International Journal for Vitamin and Nutrition Research*, pp. 1–9, 2019.
- [56] S. Kongkham, S. Sriwong, and A. Tasanarong, "Protective effect of alpha tocopherol on contrast-induced nephropathy in rats," *Nefrología*, vol. 33, no. 1, pp. 116–123, 2013.
- [57] M. Boyacioglu, H. Turgut, C. Akgullu, U. Eryilmaz, C. Kum, and O. A. Onbasili, "The effect of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rats," *The Journal of Veterinary Medical Science*, vol. 76, no. 1, pp. 1–8, 2014.



